Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus

CONCLUSIONS: The results of this study are in line with the established benefit-risk profile of pirfenidone. Therefore, pirfenidone can be considered a valuable treatment option to slow disease progression in mild-to-moderate idiopathic pulmonary fibrosis. NCT02622477.PMID:38608658 | PMC:PMC11014748 | DOI:10.1055/a-2267-2074

Source: Pneumologie - April 12, 2024 Category: Respiratory Medicine Authors: Jens Schreiber Wolfgang Sch ütte Wolfgang Koerber Bernd Seese Dirk Koschel Kathrin Neuland Christian Groh é Source Type: research